ѻý

New Depression, ADHD Drugs OK'd; DMT Microdosing; Bitcoin Addiction?

<ѻý class="mpt-content-deck">— News and commentary from the psychiatry world
MedpageToday

After some suspense -- a PDUFA date came and went with no announcement -- esketamine (Spravato) nasal spray won approval for treatment-resistant depression, in combination with a standard antidepressant.

The FDA also approved extended-released (Adhansia XR) for pediatric and adult patients with ADHD, Adlon Therapeutics announced.

Regular microdoses of (dimethyltryptamine) helped reduce anxiety and depression symptoms in rats. (ACS Chemical Neuroscience)

Roughly 25% of people with bipolar disorder might be -- specifically antidepressants that could worsen mania, a Scottish study found. (BBC)

-- a form of eating disorder where people with type 1 diabetes give themselves less insulin to lose weight -- is gaining popularity and new programs are popping up in response. (The BMJ)

A rehab center in Scotland is now treating patients for ." (CCN)

Many seniors may be for dementia, despite the Alzheimer's Association recommending it as part of an annual wellness exam for adults 65 and older. (NPR)

The FDA issued a warning letter to one of Teva's manufacturing plants for issues involving faulty . (FiercePharma)

for a large portion of kids with ADHD. (ScienceDaily)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.